CDKN2A antibody

• Background:

  CDKN2A generates several transcript variants which differ in their first exons. At least three alternatively-spliced variants encoding distinct proteins have been reported, and two are related, named p16-INK4 and p14 respetively, sharing 50% identity. The third one is completely stuctually un-related, called p14 (ARF) or p19 (ARF) . FNab06064 reacted with p16 specifically. P16 plays an important role in regulating the cell cycle, and mutations in p16 increase the risk of developing a variety of cancers, notably melanoma.

• Synonyms:

  Cyclin-dependent kinase inhibitor 2A|Cyclin-dependent kinase 4 inhibitor A (CDK4I) |Multiple tumor suppressor 1 (MTS-1) |p16-INK4a (p16-INK4, p16INK4A) |CDKN2A|CDKN2|MTS1

• Gene ID:

  1029

• UniProt:

  P42771

• Host:

  Rabbit

• Reactivity:

  Human

• Immunogen:

  Cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)

• Target:

  CDKN2A

• Clonality:

  Polyclonal

• Isotype:

  IgG

• Applications:

  ELISA, WB, IF, IP, IHC, FC

• Field of Research:

  Metabolism, Immunology, Cell Division and Proliferation, Cancer

• Purification:

  Immunogen affinity purified

• Dilution:

  WB: 1:500-1:5000; IP: 1:500-1:5000; IHC: 1:50-1:500; IF: 1:20-1:200

• Purity:

  ≥95% as determined by SDS-PAGE

• Form:

  Liquid

• Molecular Weight:

  16-18 kDa

• Shipping Conditions:

  4°C with ice bag

• Storage Conditions:

  PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20°C for 12 months (Avoid repeated freeze / thaw cycles.)

• Tested Applications:

  ELISA, WB, IF, IP, IHC, FC

• Immunogen Sequence:

  1-156aa